Sheeza Ali

Sheeza Ali

Auto-generated profile, based on publicly available information

Sheeza Ali

School of Medicine, The Maldives National University, Male’, Maldives

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2020 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
Kannan SubbaramKannan Subbaram
Kannan Subbaram
Kannan SubbaramKannan Subbaram
Kannan Subbaram
SASheeza Ali
Sheeza Ali
HKHemalatha Kannan
Hemalatha Kannan
Coronavirus disease – 2019 (COVID-19) pandemic, due to severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2), is posing a severe bio threat to the entire world. Nucleocapsids of SARS-CoV-2 and the related viruses were studied for gene and amino acid sequence homologies. In this study, we established similarities and differences in nucleocapsids in SARS-CoV-2, severe acute respiratory syndrome – coronavirus-1 (SARS-CoV-1), bat coronavirus (bat-CoV) and Middle East respiratory syndrome – coronavirus (MERS-CoV). We conducted a detailed analysis of the nucleocapsid protein amino acid and gene sequence encoding it, found in various coronavirus strains. After thoroughly screening the different nucleocapsids, we observed a close molecular homology between SARS-CoV-1 and SARS-CoV-2. More than 95% sequence similarity was observed between the two SARS-CoV strains. Bat-CoV and SARS-CoV-2 showed 92% sequence similarity. MERS-CoV and SARS-CoV-2 nucleocapsid analysis indicated only 65% identity. Molecular characterization of nucleocapsids from various coronaviruses revealed that SARS-CoV 2 is more related to SARS-CoV 1 and bat-CoV. SARS-CoV 2 exhibited less resemblance with MERS-CoV. SARS-CoV 2 showed less similarity to MERS-CoV. Thus, either SARS-CoV-1 or bat-CoV may be the source of SARS-CoV-2 evolution. Moreover, the existing differences in nucleocapsid molecular structures in SARS-CoV-2 make this virus more virulent and highly infectious, which means that the non-identical SARS-CoV-2 genes (which are absent in SARS-CoV-1 and bat-CoV) are responsible for COVID-19 severity. We observed that SARS-CoV-2 nucleocapsid from different locations varied in amino acid sequences. This revealed that there are many SARS-CoV-2 subtypes/subsets currently circulating globally. This study will help to develop antiviral vaccine and drugs, study viral replication and immunopathogenesis, and synthesize monoclonal antibodies that can be used for precise COVID-19 diagnosis, without false-positive/false-negative results.

5 June 2025 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
FSFathimath Ina Shareef
Fathimath Ina Shareef
Kannan SubbaramKannan Subbaram
Kannan Subbaram
RFRazana Faiz
Razana Faiz
SASheeza Ali
Sheeza Ali
Bacteria Associated with Prostate Cancer Progression and New Strategy in the Treatment

31 August 2025 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
AIAminath Efa Ibrahim
Aminath Efa Ibrahim
Kannan SubbaramKannan Subbaram
Kannan Subbaram
RFRazana Faiz
Razana Faiz
SASheeza Ali
Sheeza Ali
Novel approach in HIV therapy: lipid nanoparticle-based mRNA delivery technology using LNP X-HIV Tat-CRISPRa system

1 June 2026 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Closed access
AAAnjal Mohamed Ageel
Anjal Mohamed Ageel
Kannan SubbaramKannan Subbaram
Kannan Subbaram
SASheeza Ali
Sheeza Ali
QAQueen Alice Arul
Queen Alice Arul
Gut microbiome influences the efficacy of neuropsychiatric drugs


10 May 2026 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Closed access
PDF file
AIAminath Efa Ibrahim
Aminath Efa Ibrahim
Kannan SubbaramKannan Subbaram
Kannan Subbaram
RFRazana Faiz
Razana Faiz
SASheeza Ali
Sheeza Ali
QAQueen Alice Arul
Queen Alice Arul
Exosome Derived Micro RNA: A Promising Modality in the Treatment of Spinal Cord Injury and Peripheral Neuropathy